<unk>  (INN) is a quinolone antibiotic for the treatment of Gram-positive and Gram-negative bacterial infections.<unk>  was discovered by Toyama Chemical Co., Ltd. of Tokyo, Japan, and is currently being marketed in Japan under the tradename Geninax. Schering-Plough holds worldwide rights for<unk> , except for Japan, South Korea, and China.
On February 13, 2006, Schering-Plough announced that the United States Food and Drug Administration has accepted the New Drug Application (NDA) for<unk> , and has been granted a 10-month review.
Schering-Plough later withdrew its application to the United States Food and Drug Administration, FDA, (August 20, 2006) for approval of the antibiotic<unk> .
The European Medicines Agency (EMEA) had also been formally notified by Schering-Plough Europe (July 28 2007) of its decision to withdraw the application for a centralized marketing authorization for<unk>  as well.  Based on the CHMP review of the data regarding safety and efficacy (risk/benefit), the CHMP considered the application for<unk>  to be unapprovable.
Garenoxacin
Azithromycin 
Enoxacin
Telithromycin
Roxithromycin
Levofloxacin 
Dirithromycin
Fleroxacin